Abstract: An ultrasonic diagnostic device according to an embodiment includes processing circuitry. The processing circuitry estimates a health state on the basis of a measurement value measured using ultrasonic image data. The processing circuitry determines an additional examination used to diagnose the health state, on the basis of the estimated health state. The processing circuitry outputs information indicative of the health state and the additional examination.

Abstract: Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.

Abstract: A method is provided that allows the sulfur component concentration in gasoline to be estimated to high precision. The measuring method of the disclosure is a method of measuring the concentration of sulfur components in gasoline that contains sulfur components and aromatic components. The measuring method of the disclosure comprises: (A1) removing a portion of the gasoline by gasification to lower the proportion of the aromatic component concentration with respect to the sulfur component concentration in the gasoline, (A2) measuring values related to the refractive index of the gasoline, and (A3) measuring the sulfur component concentration in the gasoline based on the values related to the refractive index.

Abstract: Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.

Abstract: Provided are a determination method and a kit both for determining the possibility of the occurrence of deterioration of a renal function in the future. A method according to one aspect of the present invention involves a step of determining the level of Gal?1-3GalNAc and/or Sia?2-6Gal/GalNAc in a sample collected from a subject. A kit according to one aspect of the present invention includes a lectin capable of binding to Gal?1-3GalNAc and/or Sia?2-6Gal/GalNAc.

Abstract: The present invention provides a novel compound that can be used as a lactate dehydrogenase inhibitor or an active ingredient of a medicament such as an antiepileptic agent and an anti-cancer agent, and particularly, provides a novel compound excellent in metabolic stability. The novel compound according to the present invention is a compound represented by the following formula (1). In formula (1), R represents any substituent (for example, a monovalent substituent of an aromatic or non-aromatic 3 to 14-membered ring which may be unsubstituted or substituted and monocyclic or polycyclic), Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh and Ri each represent a hydrogen atom or any substituent (for example, Ra to Ri are all hydrogen atoms, or Re, Rf, Rg, Rh and Ri are hydrogen atoms and at least one of Ra, Rb, Rc and Rd is any substituent).

Abstract: An RNA methyltransferase inhibitor comprising sulfonamide-based compounds and/or pyrazoline-based compounds is provided

Abstract: The present invention relates to a method including culturing a C1 compound-assimilating bacterium, which is a methylotroph, and/or a yeast by using a medium comprising, for example, a C1 compound and/or glycerol as a carbon source, to thereby produce EGT.

Abstract: An object provide a technique capable of measuring temperature on the basis of optically detected magnetic resonance with higher precision, The object is achieved by a method for measuring the temperature of an object on the basis of optically detected magnetic resonance of an inorganic fluorescent particle, including (a) irradiating the object, containing the inorganic fluorescent particle with each of multiple microwaves having different frequencies, (b) measuring the fluorescence intensities of the inorganic fluorescent particle with individual photon counters at the time of irradiation of respective microwaves, (c) correcting the fluorescence intensities on the basis of dependencies in the number of pulse measurements between the photon counters and (d) Calculating the temperature of the object on the basis of the obtained fluorescence intensity with the correction values.

Abstract: One aspect of the present disclosure relates to a method for manufacturing a spun yarn made of carbon nanotubes. The method includes: a spun yarn precursor ? production step of producing a spun yarn precursor ? by pulling a plurality of carbon nanotubes from a carbon nanotube forest and spinning the carbon nanotubes while applying a tension of 6 mN or less per centimeter of a width of the carbon nanotube forest to the carbon nanotubes; a spun yarn precursor ? production step of producing a spun yarn precursor ? by applying a higher tension than in the spun yarn precursor ? production step to the spun yarn precursor ? to densify the spun yarn precursor ?; and a spun yarn production step of producing the spun yarn by electrically heating the spun yarn precursor ? while applying a tension to the spun yarn precursor ?.

Abstract: The present invention relates to a method including culturing a C1 compound-assimilating bacterium, which is a methylotroph, and/or a yeast by using a medium comprising, for example, a C1 compound and/or glycerol as a carbon source, to thereby produce EGT.

Abstract: An embodiment relates to a method of evaluating a lymphatic system function including: selecting one or a plurality of lymphatic routes to be evaluated from a plurality of lymphatic routes existing in four limbs; determining an injection site of a visualization agent based on information on the selected lymphatic route and injection sites of peripheries of the four limbs corresponding to the selected lymphatic route; injecting the visualization agent from the selected injection site; and visualizing the injected visualization agent and evaluating functions of the one or plurality of lymphatic routes to be evaluated.

Abstract: An ultrasonic diagnostic device according to an embodiment includes processing circuitry. The processing circuitry estimates a health state on the basis of a measurement value measured using ultrasonic image data. The processing circuitry determines an additional examination used to diagnose the health state, on the basis of the estimated health state. The processing circuitry outputs information indicative of the health state and the additional examination.

Abstract: The present invention relates to a method including culturing a C1 compound-assimilating bacterium, which is a methylotroph, and/or a yeast by using a medium comprising, for example, a C1 compound and/or glycerol as a carbon source, to thereby produce EGT.

Abstract: A method is provided that allows the sulfur component concentration in gasoline to be estimated to high precision. The measuring method of the disclosure is a method of measuring the concentration of sulfur components in gasoline that contains sulfur components and aromatic components. The measuring method of the disclosure comprises: (A1) removing a portion of the gasoline by gasification to lower the proportion of the aromatic component concentration with respect to the sulfur component concentration in the gasoline, (A2) measuring values related to the refractive index of the gasoline, and (A3) measuring the sulfur component concentration in the gasoline based on the values related to the refractive index.

Abstract: The present invention provides: a complex of a mercaptoundecahydrodecaborate (BSH) and a peptide, the complex for boron neutron capture therapy (BNCT); a method for producing the complex; and a cancer therapy using the complex.

Abstract: Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.

Abstract: The present invention provides: a complex of a mercaptoundecahydrodecaborate (BSH) and a peptide, the complex for boron neutron capture therapy (BNCT); a method for producing the complex; and a cancer therapy using the complex.

Abstract: The present invention provides: a complex of a mercaptoundecahydrodecaborate (BSH) and a peptide, the complex for boron neutron capture therapy (BNCT); a method for producing the complex; and a cancer therapy using the complex.

Abstract: This invention provides an anti-REIC antibody that specifically recognizes a cancer-associated protein (REIC/Dkk-3) and enables monitoring of cancer treatment effects involving the use of the REIC/Dkk-3 gene or the REIC/Dkk-3 protein as a medicine. This invention also provides a method of diagnosis involving the use of such antibody.